Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CLX
Coverage 166,458 Raw stories ingested 21,877 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 33s ago
  • FMP Forex News Fetch every 5 min 1m ago
  • CoinGecko News Fetch every 5 min 3m ago
  • FIO Stock News Fetch every 10 min 6m ago
  • Patria Stock News Fetch every 10 min 6m ago
  • Editorial rewrite Rewrite every minute 33s ago
  • Asset sync Assets every 1 hour 55m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-09-03 18:13 6d ago
2026-09-03 11:50 6d ago
Cloroxu klesla hrubá marže na 41,3 %
CLX Clorox
FMP Stock News 78
Original source text
Key Takeaways Clorox's FY26 fourth-quarter gross margin fell 520 basis points y/y to 41.3%.Higher inflation and unfavorable mix more than offset Clorox's cost-saving benefits in the quarter.Clorox expects the FY27 gross margin of 42% as inflation and negative mix remain the key headwinds. The Clorox Company (CLX - Free Report) is leaning on productivity initiatives and cost savings to counter persistent inflationary pressure, but near-term margin protection remains challenging. In the fourth quarter of fiscal 2026, the gross margin contracted 520 basis points year over year to 41.3%. Management attributed the decline mainly to higher-than-normal inflation and unfavorable mix, which more than offset benefits from cost-saving initiatives. The comparison also included about 150 basis points of pressure from lower operating leverage related to the ERP transition and another 150 basis points from GOJO acquisition-related inventory step-up.

Clorox continues to strengthen its cost structure. In fiscal 2026, the company expanded its cost-saving programs and established infrastructure designed to improve operational efficiency and generate funds for reinvestment. With the ERP implementation now completed, management is shifting from stabilization to optimization, with a focus on capturing productivity benefits, removing costs and realizing the system’s full potential.

Still, inflation is likely to remain a significant headwind in fiscal 2027. Clorox expects volatility in energy and commodity markets, elevated logistics expenses, and supply-chain pressures to keep input-cost inflation sticky. The company projects fiscal 2027 gross margin of 42%, with stronger-than-normal inflation and negative mix expected to more than offset holistic margin-management benefits.

Thus, cost savings should provide an important cushion, but they may not fully offset inflation in the near term. Longer term, productivity gains, pricing actions and disciplined margin management could support a gradual margin recovery.

Zacks Rundown for CloroxCLX shares have risen 5.2% in the past three months compared with the industry and the Consumer Staples sector’s growth of 7.1% and 5.8%, respectively. The Zacks Rank #5 (Strong Sell) company has outpaced the S&P 500’s decline of 0.3% in the same period.

Clorox’s 3-Month Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, CLX is trading at a forward price-to-earnings ratio of 15.97X, lower than the industry’s 18.74X multiple.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Clorox’s fiscal 2027 and 2028 earnings implies year-over-year growth of 6% and 8.9%, respectively. Earnings estimates for fiscal 2027 and 2028 have moved down 2.8% and 1.7% in the past 30 days.

Image Source: Zacks Investment Research

Three Stocks Looking GoodThe Vita Coco Company Inc. (COCO - Free Report) is the leading coconut water brand in the United States, leveraging its strong brand equity, expanding global presence and asset-light business model to capitalize on the growing demand for healthier hydration beverages. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Vita Coco’s current financial-year sales and earnings indicates growth of 31.6% and 64.7%, respectively, from the prior-year reported levels. COCO delivered a trailing four-quarter earnings surprise of 21.9%, on average.

National Vision Holdings, Inc. (EYE - Free Report) is a value-focused optical retailer in the United States. The company currently carries a Zacks Rank of 2 (Buy).

The Zacks Consensus Estimate for National Vision’s current financial-year sales and earnings is expected to rise 3.8% and 22.5%, respectively, from the year-ago reported figures. EYE delivered a trailing four-quarter earnings surprise of 52.5%, on average.

Purple Innovation Inc. (PRPL - Free Report) designs and manufactures products which include mattresses, pillows and cushions, using its patented Hyper-Elastic Polymer. The company currently carries a Zacks Rank of 2.

The Zacks Consensus Estimate for Purple Innovation’s current financial-year sales and earnings indicates growth of 0.4% and 20.8%, respectively, from the year-ago reported numbers. PRPL delivered a trailing four-quarter earnings surprise of 21.3%, on average.
2026-09-02 17:50 7d ago
2026-09-02 12:31 7d ago
Clorox klesl o 9,3 %, odhady dál slábnou
CLX Clorox
FMP Stock News 78
Original source text
It has been about a month since the last earnings report for Clorox (CLX - Free Report) . Shares have lost about 9.3% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Clorox due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Clorox Q4 Earnings & Sales Top Estimates as GOJO Supports SalesClorox delivered mixed fourth-quarter fiscal 2026 results, with the top and bottom lines surpassing the Zacks Consensus Estimate. However, sales and earnings per share declined year over year due to unfavorable comparison with ERP-related shipments in the prior-year quarter, lower volume and significant gross margin pressure from higher commodity, manufacturing and logistics costs.

CLX Q4 Key Metrics & InsightsClorox posted adjusted earnings of $1.66 per share for the fourth quarter of fiscal 2026, falling 42% year over year but beating the Zacks Consensus Estimate of $1.64 by 1.2%. Lower sales and gross margin weighed on the bottom line.

Net sales declined 2% to $1.95 billion but surpassed the consensus mark of $1.91 billion by 1.8%. The GOJO acquisition contributed about 10 percentage points to sales, while organic sales fell 13% due mainly to the ERP-related shipment comparison.

CLX Margin Contracts on Costs & Lower VolumeGross profit declined 13% to $804 million from $924 million a year ago. The gross margin declined 520 basis points (bps) year over year to 41.3%. Lower volume, GOJO inventory step-up costs, higher commodity expenses, and elevated manufacturing and logistics costs more than offset savings initiatives.
The comparison with incremental shipments ahead of the prior-year ERP transition reduced the margin by about 150 bps. The GOJO inventory step-up created another roughly 150-bps drag. The adjusted gross margin, excluding acquisition and integration costs, was 42.8%.
 

Clorox Records Higher Operating ExpensesSelling and administrative expenses increased 0.7% year over year to $298 million from $296 million in the year-ago quarter. These expenses represented 15.3% of net sales and included $21 million of GOJO integration costs.
Advertising costs rose 26.3% year over year to $216 million from $171 million, and represented 11.1% of sales. Research and development expenses were unchanged at $32 million.

CLX Posts Mixed Segment ResultsHealth and Wellness sales increased 16% year over year to $860 million. The GOJO acquisition contributed about 28 percentage points to growth. Organic sales declined 12% because of the ERP-related shipment comparison, while segment adjusted EBIT fell 15% to $206 million.

Household sales decreased 18% to $524 million, led by a 16-point volume decline and two points of unfavorable price mix. The decrease reflected the ERP comparison and shipments ahead of consumption in the fiscal third quarter. Segmental adjusted EBIT plunged 56% to $69 million amid lower sales and higher commodity costs.

Lifestyle sales declined 17% year over year to $280 million. Volume fell 14 points, while unfavorable price mix reduced growth by another three points. Segment adjusted EBIT decreased 60% to $38 million, mainly because of lower revenues.

International sales increased 4% to $281 million, primarily supported by favorable foreign exchange rates. Organic sales rose 1%. Segment adjusted EBIT advanced 17% to $27 million on higher sales and cost savings.

Clorox Issues FY27 OutlookFor fiscal 2027, CLX expects net sales growth of 13-14%, including 9.5 percentage points from GOJO. Organic sales are projected to rise 3.5-4.5%, including more than 3.5 points of benefit from lapping the ERP-related inventory drawdown.

The company expects a gross margin of 42%, as stronger-than-normal inflation and unfavorable mix are anticipated to more than offset cost savings. Selling and administrative expenses are projected at 16% of sales, while advertising spending is expected to be 10%.

Adjusted earnings are forecast between $5.70 and $6.00 per share, implying growth of 3-8% year over year. Reported earnings are expected between $5.41 and $5.71 per share, including 29 cents of GOJO transaction-related costs.

CLX Cash Flow & Balance Sheet UpdateThe fiscal 2026 operating cash flow decreased 38% year over year to $612 million due to the Glad Venture Agreement termination payment. Management expects the fiscal 2027 free cash flow to be 11-13% of net sales.

Clorox ended fiscal 2026 with $143 million in cash and cash equivalents. Long-term debt rose to $3.98 billion from $2.48 billion a year earlier, while notes and loans payable increased to $1.09 billion from $4 million following the GOJO transaction.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -21.06% due to these changes.

VGM ScoresAt this time, Clorox has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Clorox has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry PlayerClorox belongs to the Zacks Consumer Products - Staples industry. Another stock from the same industry, Albertsons Companies, Inc. (ACI - Free Report) , has gained 3.2% over the past month. More than a month has passed since the company reported results for the quarter ended May 2026.

Albertsons Companies reported revenues of $24.94 billion in the last reported quarter, representing a year-over-year change of +0.2%. EPS of $0.42 for the same period compares with $0.55 a year ago.

Albertsons Companies is expected to post earnings of $0.33 per share for the current quarter, representing a year-over-year change of -25%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #5 (Strong Sell) for Albertsons Companies. Also, the stock has a VGM Score of A.
2026-08-31 17:09 9d ago
2026-08-31 05:42 9d ago
Canada Pension Plan Investment Board získala podíl v Clorox
CLX Clorox
FMP Stock News 78
Original source text
Canada Pension Plan Investment Board purchased a new position in shares of The Clorox Company (NYSE:CLX – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 32,488 shares of the company’s stock, valued at approximately $3,101,000.

Other large investors also recently modified their holdings of the company. Caitlin John LLC lifted its position in shares of Clorox by 1,807.1% during the 4th quarter. Caitlin John LLC now owns 267 shares of the company’s stock worth $27,000 after purchasing an additional 253 shares during the last quarter. Avalon Trust Co acquired a new stake in Clorox in the second quarter valued at $29,000. Darwin Wealth Management LLC acquired a new stake in Clorox in the second quarter valued at $29,000. Root Financial Partners LLC lifted its holdings in Clorox by 83.8% during the 1st quarter. Root Financial Partners LLC now owns 318 shares of the company’s stock worth $33,000 after buying an additional 145 shares during the last quarter. Finally, SHP Wealth Management purchased a new stake in Clorox during the 4th quarter worth about $35,000. 78.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth CLX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Clorox from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BNP Paribas Exane decreased their target price on Clorox from $97.00 to $95.00 and set a “neutral” rating for the company in a research note on Monday, July 20th. Deutsche Bank Aktiengesellschaft set a $98.00 price target on Clorox in a report on Tuesday, August 4th. Wells Fargo & Company increased their price target on shares of Clorox from $95.00 to $102.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 4th. Finally, Jefferies Financial Group cut shares of Clorox from a “buy” rating to a “hold” rating and cut their price objective for the stock from $125.00 to $98.00 in a report on Tuesday, July 28th. Twelve equities research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, Clorox has a consensus rating of “Reduce” and an average target price of $102.40.

Read Our Latest Research Report on CLX Clorox Stock Up 0.0% CLX opened at $102.57 on Monday. The Clorox Company has a one year low of $84.70 and a one year high of $128.90. The company has a debt-to-equity ratio of 15.80, a quick ratio of 0.38 and a current ratio of 0.66. The stock has a market capitalization of $12.40 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 3.21 and a beta of 0.54. The business’s 50-day simple moving average is $99.83 and its 200-day simple moving average is $102.60.

Clorox (NYSE:CLX – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.91 billion. Clorox had a return on equity of 522.23% and a net margin of 8.74%.The business’s revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.87 EPS. Clorox has set its FY 2027 guidance at 5.700-6.000 EPS. Analysts anticipate that The Clorox Company will post 5.8 EPS for the current year.

Clorox Increases Dividend The company also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Wednesday, August 12th were issued a $1.25 dividend. The ex-dividend date of this dividend was Wednesday, August 12th. This is an increase from Clorox’s previous quarterly dividend of $1.24. This represents a $5.00 annualized dividend and a dividend yield of 4.9%. Clorox’s dividend payout ratio is currently 103.73%.

Clorox Profile (Free Report)

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.

See Also Five stocks we like better than Clorox Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX – Free Report).

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
2026-08-21 19:48 18d ago
2026-08-21 14:56 19d ago
Clorox roste, ale brzdí ho inflace a slabá poptávka
CLX Clorox
FMP Stock News 78
Original source text
Key Takeaways Clorox's rally faces tests from inflation, softer margins and subdued underlying demand.Organic growth is expected to be flat to slightly positive excluding ERP comparison benefits.Clorox faces more than $200 million in inflation, while fiscal 2027 EPS estimates have declined. The Clorox Company (CLX - Free Report) has climbed 13.1% in the past month, rebounding as investors digest its fiscal fourth-quarter results and fiscal 2027 outlook. The advance has come despite pressure from inflation, subdued category demand and softer margins.

Clorox’s recent earnings beat, the GOJO acquisition and completion of its U.S. enterprise resource planning rollout provide reasons for optimism. The durability of the rally, however, will depend on whether those catalysts translate into better underlying sales growth and margin recovery.

What is Fueling CLX's Rebound?Fiscal fourth-quarter adjusted earnings of $1.66 per share topped the Zacks Consensus Estimate of $1.64 by 1.2%. Sales of $1.95 billion also beat the consensus mark by 1.8%, though they fell 2% year over year. GOJO added about 10 percentage points to reported sales growth, partly offsetting a 13% organic sales decline that largely reflected the ERP shipment comparison.

Image Source: Zacks Investment Research

For fiscal 2027, management expects net sales to rise 13-14%, including about 9.5 points from GOJO. Adjusted earnings per share are projected at $5.70-$6.00, up 3-8%. ERP productivity benefits are expected to begin later in the year. Home Care has posted eight consecutive quarters of share growth, while Glad Trash and Hidden Valley Ranch returned to share growth in the fiscal fourth quarter.

The Rally Still Faces Margin and Demand TestsProfitability remains the central challenge. Fiscal 2026 gross margin fell 290 basis points to 42.3%, while fourth-quarter gross margin declined 520 basis points to 41.3%. Management expects fiscal 2027 gross margin of about 42%, with cost savings more than offset by higher-than-normal inflation and negative mix. Inflation is projected to exceed $200 million, more than twice the company's historical $75-$100 million range.

Headline growth also overstates the underlying demand picture. Fiscal 2027 organic sales are expected to increase 3.5-4.5%, but more than 3.5 points of that growth comes from lapping the prior-year ERP inventory drawdown. Excluding that comparison, organic sales are expected to be flat to up slightly. Fresh Step remains early in its reset, while value-seeking consumers and a soft grilling category add risk.

Peer Trends Put CLX's Setup in ContextThe Procter & Gamble Company (PG - Free Report) reported flat organic sales in its fiscal fourth quarter and 1% organic growth for fiscal 2026. Its results show that even large branded peers are navigating a muted growth environment.

Church & Dwight Co., Inc. (CHD - Free Report) , meanwhile, posted second-quarter organic sales growth of 5.8% and a 40-basis-point increase in adjusted gross margin to 45.4%. CLX trades at 17.7X forward 12-month earnings, slightly below its sub-industry's 18.2X multiple but near the consumer staples sector's 17.2X.

Can Clorox Keep the Gains Building?Clorox can extend its rebound if GOJO integration, ERP productivity and improving market shares support healthier underlying organic growth while margins recover. The fiscal 2027 setup offers catalysts, but much of the expected top-line improvement still comes from acquisition and comparison effects rather than broad demand acceleration.

Near-term signals remain cautious. The Zacks Consensus Estimate for fiscal 2027 earnings has declined 3.8% in the past four weeks to $5.82 per share. CLX currently carries a Zacks Rank #4 (Sell), with a Value Score of C, Growth Score of D, Momentum Score of F and VGM Score of D. Recent price strength has not yet been matched by favorable earnings revisions or Style Score support, keeping execution in focus.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-08-21 19:48 18d ago
2026-08-21 15:01 19d ago
Clorox čeká růst díky GOJO, marže dál snižuje inflace
CLX Clorox
FMP Stock News 78
Original source text
Key Takeaways Clorox expects GOJO to add 9.5 points to fiscal 2027 sales growth and boost its health platform.Organic sales growth may be limited as inflation tops $200 million and negative mix pressures margins.Clorox must deliver stronger core demand and margin recovery as ERP benefits fade. The Clorox Company (CLX - Free Report) enters fiscal 2027 with a larger health-and-hygiene platform after the GOJO acquisition, but investors are weighing that growth against weaker margins and muted underlying demand. Clorox expects GOJO to add about 9.5 percentage points to fiscal 2027 net sales growth and be accretive to adjusted earnings per share.

The earnings outlook offers improvement, yet much of the reported growth comes from acquisition and enterprise resource planning (ERP) comparison effects. Persistent inflation, softer categories and negative mix keep the near-term investment case balanced rather than straightforward.

GOJO Gives Clorox a New Growth EngineClorox's fourth-quarter fiscal 2026 net sales fell 2% to $1.95 billion but beat the Zacks Consensus Estimate of $1.91 billion by 1.8%. GOJO contributed about 10 percentage points to sales growth. Health and Wellness sales increased 16% to $860 million, with the acquisition contributing about 28 points to the segment's growth.

GOJO also changes Clorox's longer-term mix. The combined global health-and-hygiene portfolio now accounts for more than half of net sales. For fiscal 2027, management expects total net sales to increase 13-14%, including the roughly 9.5-point GOJO contribution, while adjusted earnings are projected at $5.70-$6.00 per share, up 3-8%.

Margin Pressure Limits the UpsideProfitability is the main counterweight. Fiscal 2026 gross margin declined 290 basis points to 42.3%, while fourth-quarter gross margin dropped 520 basis points to 41.3%. The quarter included about 150 basis points of pressure each from the ERP shipment comparison and GOJO inventory step-up, alongside higher commodity, manufacturing and logistics costs.

Clorox expects fiscal 2027 gross margin of about 42%, with cost savings more than offset by higher-than-normal inflation and negative mix. Inflation is expected to exceed $200 million, more than twice the company's historical $75-$100 million range. Organic sales are forecast to rise 3.5-4.5%, but more than 3.5 points reflect the ERP comparison. Excluding that benefit, organic sales are expected to be flat to up slightly.

Peer Results Show a Mixed Staples BackdropThe Procter & Gamble Company (PG - Free Report) reported flat organic sales in its fiscal fourth quarter and 1% organic sales growth for fiscal 2026. That performance underscores the subdued demand environment across large branded household and personal-care categories, even for companies with broad portfolios and substantial scale.

Church & Dwight Co., Inc. (CHD - Free Report) offered a more favorable margin comparison. Its second-quarter 2026 organic sales increased 5.8%, while adjusted gross margin expanded 40 basis points to 45.4%. The contrast shows that consumer-staples companies are navigating similar inflation and value pressures with different operating outcomes.

Is CLX Stock Worth Buying Now?The GOJO acquisition gives Clorox a credible growth driver, and completed ERP investments could support productivity later in fiscal 2027. Still, the core business must show firmer organic demand and better margin progression before the growth profile looks more durable. CLX trades at 17.9X forward 12-month earnings, modestly below its sub-industry's 18.2X multiple.

Image Source: Zacks Investment Research

Near-term Zacks signals remain cautious. The Zacks Consensus Estimate for fiscal 2027 earnings is $5.82 per share and has declined 3.8% in the past four weeks. CLX currently carries a Zacks Rank #4 (Sell), along with a Value Score of C, Growth Score of D, Momentum Score of F and VGM Score of D. Under the Zacks framework, the Rank points to unfavorable earnings-revision trends, while the weaker Growth, Momentum and VGM scores provide limited support for an aggressive buying case.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-08-04 15:29 1mo ago
2026-08-04 09:22 1mo ago
Clorox překonal odhady a zvýšil výhled pro FY2027
CLX Clorox
FMP Stock News 78
Original source text
Clorox Co (NYSE:CLX) reported better-than-expected earnings for the fourth quarter on Monday.

The company posted quarterly earnings of $1.66 per share which beat the analyst consensus estimate of $1.65 per share. The company reported quarterly sales of $1.948 billion which beat the analyst consensus estimate of $1.898 billion.

Clorox said it sees FY2027 adjusted EPS of $5.70-$6.00, versus market estimates of $5.97. The company expects sales of $7.594 billion-$7.661 billion, versus estimates of $7.501 billion.

Clorox shares rose 1.8% to $100.00 in pre-market trading.

These analysts made changes to their price targets on Clorox following earnings announcement.

Evercore ISI Group analyst Javier Escalante maintained the stock with an Underperform rating and raised the price target from $98 to $99. Wells Fargo analyst Chris Carey maintained the stock with an Equal-Weight rating and raised the price target from $95 to $102. Considering buying CLX stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-08-04 01:03 1mo ago
2026-08-03 20:05 1mo ago
Clorox čeká stagnaci tržeb a vyšší inflaci
CLX Clorox
FMP Stock News 78
Original source text
5 High-Yield Stocks That Could Help Cushion Market VolatilityClorox NYSE: CLX said it is entering fiscal 2027 with improving market-share trends, a completed enterprise resource planning implementation and a plan to offset more than $200 million in expected supply-chain inflation through productivity initiatives and targeted pricing.

Chair and CEO Linda Rendle said the company operated through fiscal 2026 in an environment marked by value-seeking consumers, heightened competition, inflation and macroeconomic uncertainty. Clorox has responded by adjusting product offerings, price-pack architecture, promotions, brand investment and distribution, while continuing its broader operational transformation.

Get Clorox alerts:

3 Defensive Stocks to Buy as Economic Uncertainty Lingers“While the majority of our businesses are performing at or above expectations, we have taken decisive actions to improve in the areas that are not yet delivering what we expect,” Rendle said. She said the company saw sequential improvement in consumption and market share during fiscal 2026, with consumption returning to flat in the fourth quarter and aggregate share down only one-tenth of a percentage point.

Fiscal 2027 outlook includes muted category growth Rendle said Clorox expects category growth to remain muted in fiscal 2027, broadly consistent with fiscal 2026, as consumers continue seeking value. The company’s outlook assumes continuity in category conditions and does not contemplate significant disruption from inflation or geopolitical developments.

3 Dividend Stocks Raising Payouts—and Backing It Up With ResultsClorox expects organic sales to be flat to slightly higher for the year, with a slower first quarter primarily due to timing effects in Kingsford grilling products and promotions. Rendle described the first-quarter impact as a “blip,” saying the rest of the year, particularly the back half, should more closely resemble fiscal 2026 trends.

Kingsford faced a difficult grilling season as weather affected key holidays. Rendle said Memorial Day was unusually cool and wet across much of the U.S., while widespread heat advisories during the July 4 weekend discouraged grilling. Retailers also emphasized smaller sizes on promotion to appeal to value-oriented shoppers. Clorox plans to adjust its merchandising approach next season by encouraging earlier seasonal purchases.

Management expects to continue improving market share in fiscal 2027. Rendle highlighted eight consecutive quarters of share growth in home care, as well as continued share gains in professional and international businesses. The company also cited improving results in Glad and Hidden Valley Ranch, while identifying litter and Kingsford as areas where further progress is needed.

Inflation, pricing and margins CFO Luc Bellet said Clorox expects fiscal 2027 inflation of more than $200 million, more than double the company’s historical range of $75 million to $100 million. The outlook assumes Brent crude oil averages about $90 a barrel and includes cost pressures beyond commodities, including supplier costs, ocean freight, trucking and other logistics expenses.

Bellet said inflation is expected to be more pronounced in the first half of the fiscal year. Productivity will be the company’s primary offset, supplemented by selective pricing and other revenue-management actions. Clorox expects to begin recovering gross margin in the second half, although it does not expect to fully recover margin for the full year. The company expects to exit fiscal 2027 with a stronger gross margin.

Rendle said Clorox is taking a more selective approach to pricing than in prior inflationary periods, following several substantial price increases during 2022 and 2023. The company is implementing a regular price increase in Glad trash because of that category’s resin exposure, while using targeted pricing elsewhere in the portfolio.

“Pricing is only one tool in the toolbox,” Rendle said, pointing to revenue growth management, price-pack architecture, cost savings and innovation as additional levers. She said management does not see a structural loss of pricing power in its categories, but views the current environment as unusual because it follows back-to-back inflation cycles and pressure on consumer budgets.

GOJO acquisition and operating transformation Management said the integration of GOJO, which brings the Purell brand into Clorox’s portfolio, is proceeding as planned and in some areas ahead of plan. Rendle said the business performed ahead of its fourth-quarter targets, while Bellet said GOJO was accretive rather than dilutive to adjusted earnings per share in the quarter.

Bellet said GOJO is expected to be accretive to adjusted EPS in fiscal 2027 and is expected to grow at a mid-single-digit rate before potential revenue synergies. As those synergies are realized, management expects growth in the business could reach the mid- to high-single digits for several years.

The CFO also noted that GOJO’s business-to-business model has a different profit-and-loss profile than Clorox’s legacy operations, including lower advertising spending as a percentage of sales and higher selling, general and administrative expenses.

Clorox completed its ERP implementation and is now focused on stabilizing and optimizing the system. Bellet said the company expects supply-chain and administrative benefits to build later in fiscal 2027 and into the following year. Potential benefits include improved planning, lower inventory, automation, more responsive demand fulfillment and increased use of global business services.

Litter turnaround and CEO search Rendle said litter remains the company’s principal work in progress following the cyberattack and operational disruptions of prior years. The company has restored lost distribution, but is continuing to overhaul the Fresh Step brand through product improvements, packaging changes, marketing, e-commerce upgrades and targeted pricing.

Clorox reduced dust in certain Fresh Step products, expanded investment in lightweight litter and changed packaging and marketing. Rendle said more innovation is planned for the back half of fiscal 2027, though she cautioned that rebuilding consumer awareness, repeat purchases and category momentum will take time.

Rendle also provided an update on Clorox’s CEO succession process. She previously informed the board of her intention to step down due to personal health challenges. She said she is cancer-free, feels well and remains focused on running the company. The board has hired an external search firm and the process is progressing according to its expected timeline.

Clorox expects fiscal 2027 free cash flow to remain within its targeted range of 11% to 13% of sales. Bellet said the company remains committed to its dividend, describing the currently elevated payout ratio as transitory while gross margins rebuild.

About Clorox (NYSE:CLX)The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company's flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox's diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Clorox Right Now?Before you consider Clorox, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.

While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
2026-08-03 20:15 1mo ago
2026-08-03 16:10 1mo ago
Clorox čeká v roce 2027 růst tržeb o 13 až 14 procent
CLX Clorox
FMP Stock News 92
Original source text
Delivers Q4 results in line with expectations while advancing strategic investments

, /PRNewswire/ -- The Clorox Company (NYSE: CLX) today reported results for the fourth quarter and fiscal year 2026, which ended June 30, 2026.

Fourth-Quarter Fiscal Year 2026 Summary

In April 2026, the company completed the acquisition of GOJO Industries, Inc. (GOJO), which now operates as Clorox Purell and includes the Purell® brand and a portfolio of health and hygiene solutions.

The following is a summary of key fourth-quarter results. All comparisons are with the fourth quarter of fiscal year 2025 unless otherwise stated.

Net sales decreased 2% to $1.95 billion. The GOJO acquisition added about 10 points. Organic sales1 decreased 13%, primarily due to lapping the incremental shipments related to the ERP transition, which is about 13.5 points. Gross margin decreased 520 basis points to 41.3% from 46.5%, primarily driven by lower volume, impact from the inventory step-up of the GOJO acquisition, higher commodity costs and higher manufacturing and logistics costs, partially offset by cost savings. The ERP-related shipment comparison and GOJO inventory step-up each reduced gross margin by about 150 basis points. Diluted net earnings per share (diluted EPS) decreased 50% to $1.34 from $2.68 in the year-ago quarter. The decrease includes GOJO transaction-related costs primarily related to inventory step-up and integration costs, partially offset by the impact of lapping of the company's investment in its digital capabilities and productivity enhancements compared to the prior period. Adjusted EPS1 decreased 42% to $1.66 from $2.87 in the year-ago quarter, primarily due to lower net sales and lower gross margin. The impact of ERP-related shipment comparison was about 90 cents. "Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment," said Chair and CEO Linda Rendle. "Throughout fiscal year 2026, we strengthened our business despite continued consumer and macroeconomic pressures. We expanded our portfolio through the acquisition of GOJO Industries, completed our U.S. ERP implementation, a foundational modernization of the systems and processes that underpin every aspect of our operations, while advancing our digital capabilities. Together, these actions have strengthened our foundation and position us well to navigate a challenging operating environment as we work to return to organic sales growth. We exited the year with improved execution, a stronger innovation pipeline and a clear plan to deliver superior value across our portfolio, better meeting evolving consumer needs and driving long-term growth.

As we begin fiscal year 2027, we expect the operating environment to remain challenging, with continued cost volatility and a value-seeking consumer. Even so, we are starting the year from a stronger position to execute our strategy with discipline, build on the momentum we've created and deliver greater superiority across our portfolio. We are confident that the investments we've made in our brands, capabilities and products position us to deliver long-term value for shareholders."

This press release includes certain Non-GAAP financial measures. See "Non-GAAP Financial Information" at the end of this press release for more details.  

__________________

1 Organic sales growth/(decrease) and adjusted EPS are non-GAAP measures. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.

Strategic and Operational Highlights

The following are highlights of business achievements for fiscal year 2026:

Completed the acquisition of GOJO, unlocking new growth synergies across the combined portfolio of Clorox Purell and Clorox Professional by bringing together complementary brands and capabilities to strengthen the company's health and hygiene platform. Clorox's global health and hygiene portfolio now represents more than half of net sales. Continued to invest behind value superiority and consumer-centered experiences by nearly doubling innovation across its expanded portfolio in fiscal year 2026, including the launch of Clorox PURE and Clorox Screen+ Sanitizing Wipes, expanded professional hygiene solutions from Clorox Healthcare and Purell, Fresh Step Lightweight Litter, Glad ForceFlex MaxStrength LeakGuard Trash Bags, new lip and body care offerings from Burt's Bees, as well as new flavors and scents across Clorox, Glad, Hidden Valley Ranch and Pine-Sol. Completed its U.S. ERP implementation, marking the conclusion of the company's five-year digital transformation investment, modernizing the business to optimize operations and reduce costs by leveraging end-to-end data and insights to support decision-making. Implemented a simplified operating structure to streamline leadership oversight, align resources to drive the company's strongest growth opportunities, advance portfolio optimization efforts and support faster execution across the enterprise. The company was recognized among America's Best Companies by Time Magazine, as well as America's Best Employers for Company Culture and 2026 Net Zero Leaders by Forbes. Key Segment Results

The following is a summary of key fourth-quarter results by reportable segment. All comparisons are with the fourth quarter of fiscal year 2025, unless otherwise stated.

Health and Wellness (Cleaning; Professional Products, now including Clorox Purell)             

Net sales increased 16%, driven by 10 points of higher volume and 6 points of favorable price mix. The GOJO acquisition contributed approximately 28 points to net sales growth. Organic sales declined 12%, primarily driven by the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter. Excluding the impact of these incremental shipments, organic sales would have increased in the quarter. Segment adjusted EBIT2 decreased 15%, primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter, higher advertising investments and manufacturing and logistics costs, partially offset by the benefit of the GOJO acquisition. Household (Bags and Wraps; Cat Litter; Grilling)

Net sales decreased 18%, driven by 16 points of lower volume and 2 points of unfavorable price mix. The volume decrease is primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter and shipment ahead of consumption in the third quarter. Segment adjusted EBIT decreased 56%, primarily due to lower net sales and higher commodity costs, partially offset by cost savings. Lifestyle (Food; Water Filtration; Natural Personal Care)

Net sales decreased 17%, driven by 14 points of lower volume and 3 points of unfavorable price mix. The volume decrease is primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter. Segment adjusted EBIT decreased 60%, primarily due to lower net sales. International (Sales Outside the U.S.)

Net sales increased 4%, primarily driven by favorable foreign exchange rates. Organic sales grew 1%. Segment adjusted EBIT increased 17%, primarily due to higher net sales and cost savings. __________________

2 Adjusted EBIT is a non-GAAP measure. See Non-GAAP Financial Information at the end of this press release for reconciliations to the most comparable GAAP measures.

Fiscal Year 2026 Summary

The following is a summary of key fiscal year 2026 results. All comparisons are to fiscal year 2025.

Net sales decreased 5% to $6.72 billion. The GOJO acquisition added about 3 points. Organic sales decreased 8%, mainly due to lapping incremental shipments related to the ERP transition in the fourth quarter, which is about 7.5 points. Gross margin decreased 290 basis points to 42.3% from 45.2% in the year-ago period, primarily driven by lower net sales and higher manufacturing and logistics costs, partially offset by cost savings. The ERP-related shipment comparison reduced gross margin by about 100 basis points. The negative impact from GOJO transaction-related costs was about 50 basis points, primarily behind inventory step-up. Diluted EPS decreased 26% to $4.81 from $6.52 in the year-ago period, which includes lapping the cyberattack insurance recovery benefit from the prior period, GOJO transaction-related costs primarily related to inventory step-up and integration costs, partially offset by lower costs related to the company's investment in its digital capabilities and productivity enhancements in the current period and the loss on sale of the VMS business in the prior period. Adjusted EPS decreased 28% to $5.53 from $7.72, primarily due to lower net sales and higher manufacturing and logistics costs, partially offset by cost savings. The ERP-related shipment comparison reduced adjusted EPS by about 90 cents. Net cash provided by operations was $612 million compared to $981 million in fiscal year 2025, representing a 38% decrease. The decrease was primarily driven by the Glad Venture Agreement termination payment. ERP Transition Impact

During the fourth quarter of fiscal year 2025, retailers placed orders in advance of the company's ERP system transition in the U.S. to minimize any potential inventory impacts during the implementation phase. The shipments of incremental inventory provided a benefit to fourth quarter 2025 net sales. These shipments added about 3.5 points of sales and about 90 cents earnings per share to fiscal year 2025. 

In fiscal year 2026, retailers drew down on this inventory during the company's ERP transition period, resulting in lower shipments. From a year-over-year sales growth perspective, the reduction in sales from this inventory drawdown translates to about 7.5 points of decline as compared to the higher base in fiscal year 2025. Similarly, this inventory drawdown reduced fiscal year 2026 earnings per share by about 90 cents. In comparison to the higher base in fiscal year 2025, this results in a year-over-year reduction of about 28% to fiscal year 2026 diluted earnings per share and about 23% to fiscal year 2026 adjusted earnings per share.

In fiscal year 2027, the company will lap the above-described inventory drawdown, which is expected to result in more than 3.5 points of benefit to net sales growth. This lap is also expected to benefit the company's adjusted EPS growth.

Fiscal Year 2027 Outlook

The following are the key drivers of the company's fiscal year 2027 outlook:

Net sales are expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition. Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year. Gross margin is expected to be about 42%, reflecting higher-than-normal inflationary headwinds and negative mix more than offsetting the benefits from cost savings. This includes about 20 basis points of negative impact primarily related to the GOJO inventory step-up. Selling and administrative expenses are expected to be about 16% of net sales. This includes about 40 basis points of negative impact from GOJO transaction-related costs. Advertising and sales promotion spending is expected to be about 10% of net sales. This assumes over 11% of net sales for its retail businesses. The company's effective tax rate is expected to be about 23%.  Diluted EPS is expected to be between $5.41 and $5.71, a year-over-year increase of 12% to 19%, respectively. This includes about 29 cents of impact from transaction-related costs associated with the GOJO acquisition, which are expected to flow through cost of goods sold as well as selling and administrative expenses. Adjusted EPS is expected to be between $5.70 and $6.00, or an increase between 3% and 8%, respectively. These growth rates include the benefit of lapping the inventory drawdown related to the ERP transition in the prior year.

Net sales (percentage change versus the year-ago period)

Fiscal year
2025 full year

Fiscal year
2026 full year

Fiscal year 2027 full year
outlook

Impact

Impact

Low

High

Net sales growth / (decrease) (GAAP)

0 %

(5) %

13 %

14 %

Add/(Subtract): Divestitures/acquisitions

5

(3)

(9.5)

(9.5)

Organic sales growth / (decrease) (non-GAAP)

5 %

(8) %

3.5 %

4.5 %

Note: Approximate impact from incremental shipments related to ERP transition

3.5 %

(7.5) %

           > 3.5%

> 3.5%

Diluted earnings per share

Fiscal year
2025 full year

Fiscal year
2026 full year

Fiscal year 2027 full year
outlook

Impact

Impact

Low

High

As estimated (GAAP)

$           6.52

$           4.81

$           5.41

$           5.71

Loss on divestiture

0.94





Acquisition and integration costs



0.36

0.29

0.29

Cyberattack costs, net of insurance recoveries

(0.42)





Digital capabilities and productivity enhancements investment

0.68

0.36





As adjusted (non-GAAP)

$           7.72

$           5.53

$           5.70

$           6.00

Note: Approximate impact from incremental shipments related to ERP transition

$           0.90

$          (0.90)

$              —

$

Clorox Earnings Conference Call Schedule

At approximately 4:15 p.m. ET today, Clorox will post prepared management remarks regarding its fourth-quarter and fiscal year 2026 results.

At 5 p.m. ET today, the company will host a live Q&A audio webcast with Chair and CEO Linda Rendle and Chief Financial Officer Luc Bellet to discuss the results.

Links to the live (and archived) webcast, press release and prepared remarks can be found at Clorox Quarterly Results.

For More Detailed Financial Information

Visit the company's Quarterly Results for the following: 

Supplemental unaudited volume and sales growth information  Supplemental unaudited gross margin drivers information   Supplemental unaudited cash flow information and free cash flow reconciliation  Supplemental unaudited reconciliation of earnings (losses) before income taxes to EBIT and adjusted EBIT Supplemental unaudited reconciliation of adjusted earnings per share (EPS) and adjusted effective tax rate (ETR) Note: Percentage and basis-point, or point, changes noted in this press release are calculated based on rounded numbers, except for per-share data and the effective tax rate.

About The Clorox Company

The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Headquartered in Oakland, California since 1913, Clorox integrates sustainability into how it does business. Driven by consumer-centric innovation, the company is committed to delivering clearly superior experiences through its trusted brands including Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr®, PineSol® and Purell® as well as international brands such as Chux®, Clorinda® and Poett®. Visit thecloroxcompany.com to learn more.

CLX-F

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, regarding the acquisition of GOJO, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, including as a result of the GOJO acquisition, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "will," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management's expectations, are described in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2025, as updated from time to time in the company's Securities and Exchange Commission filings. These factors include, but are not limited to: the risks arising from the integration of the GOJO business, including the ability to successfully integrate GOJO's operations, systems, controls, culture, customers, suppliers and personnel, and to realize the anticipated benefits and synergies of the acquisition, including cost savings and growth opportunities, when expected or at all; the risks of adapting to GOJO's business-to-business ("B2B") operating model, including differences in distribution channels, go-to-market strategies, margin profiles and customer requirements, increased exposure to customer concentration and consolidation among distributors, group purchasing organizations, health systems and other institutional customers in B2B channels, and potential channel conflict with the company's consumer business; the risk of increased regulatory exposure resulting from GOJO's portfolio of products subject to U.S. Food and Drug Administration oversight, including products regulated as cosmetics and over-the-counter drugs; the risk of unexpected costs or expenses resulting from the GOJO acquisition; the risk of litigation related to the GOJO acquisition, including resulting expense; the risk of impairment charges related to intangible assets acquired in connection with the GOJO acquisition; the risks related to disruption of the company's ongoing business operations and diversion of management time and resources from the GOJO acquisition; the risk that the GOJO acquisition may have an adverse effect on the company's ability to retain key personnel, customers and suppliers; unfavorable general economic and geopolitical conditions beyond the company's control, including inflation, supply chain disruptions, labor shortages, wage pressures, fuel and energy costs, interest rate fluctuations, foreign currency exchange rate fluctuations, weather events or natural disasters, disease outbreaks or pandemics, terrorism, and unstable geopolitical conditions, including active armed conflicts and military hostilities in the Middle East, such as the ongoing conflict involving Iran, and rising tensions in various parts of the world, as well as macroeconomic and geopolitical volatility and uncertainty resulting from a number of these and other factors, such as actual and potential shifts in U.S. and foreign trade policies, escalating trade tensions between the U.S. and its trading partners, especially China, the potential expansion of sanctions regimes, and disruptions to global markets or transportation routes, particularly due to the imposition of U.S. and retaliatory tariffs; the impact of market and category declines, and the company's product and geographic mix on its ability to meet sales growth targets; the company's ability to successfully execute or realize the anticipated benefits of its strategic or transformational initiatives, including the ERP transition and the related timing and volume of shipment movement related to the ERP transition and the shift towards a simplified operating structure; the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences; intense competition in the company's markets; volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services; risks related to supply chain issues, product shortages and disruptions to the business, as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers; risks related to the company's use of and reliance on information technology systems, including potential and actual security breaches, cyberattacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or company information, business, service or operational disruptions, or that impact the company's financial results or financial reporting, or any resulting unfavorable outcomes, increased costs or legal proceedings; the ability of the company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries; the ability of the company to successfully manage global political, legal, tax and regulatory risks, including due to regulatory uncertainty and lack of regulatory convergence among different jurisdictions; lower revenue, increased costs, other financial statement impacts or reputational harm resulting from government actions, compliance with regulations, or any material costs imposed by changes in regulation; the company's ability to maintain its business reputation and the reputation of its brands and products; dependence on key customers and risks related to customer consolidation and ordering patterns; the company's ability to attract and retain key personnel, which may continue to be impacted by challenges in the labor market, such as increasing labor costs and sustained labor shortages, as well as the company's ability to manage leadership transitions, including the previously announced CEO succession, and retain and integrate key employees of acquired businesses; changes to the company's processes and procedures as a result of its digital capabilities and productivity enhancements that may result in changes to the company's internal controls over financial reporting; risks related to the company's continued operation of the Glad business; risks related to international operations and international trade, including changing macroeconomic conditions as a result of inflation, volatile commodity prices and increases in raw and packaging materials prices, labor, energy and logistics; global economic or political instability; foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade policy and tariffs, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; potential operational or supply chain disruptions from wars and military conflicts, including active armed conflicts and military hostilities in the Middle East, such as the ongoing conflict involving Iran, and/or Ukraine and rising tensions in various parts of the world, such as between China and Taiwan; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies; and the possibility of nationalization, expropriation of assets or other government action or inaction, including the impacts of any prolonged U.S. government shutdown; the impact of climate change and other sustainability issues on sales, operating costs, reputation or stakeholder relationships; the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls; risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill, and integration costs and potential contingent liabilities related to those transactions; the accuracy of the company's estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based; risks related to the company's reliance on third-party service providers, including inability to meet cost savings or efficiencies, business or systems disruptions, and other liabilities, including legal or regulatory risk; environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances; the company's ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the company of third-party intellectual property rights; the effect of the company's indebtedness and credit rating, including increased indebtedness resulting from the GOJO acquisition and Glad joint venture buyout, on its business operations and financial results and the company's ability to access capital markets and other funding sources, as well as the cost of capital to the company; the company's ability to pay and declare dividends or repurchase its stock in the future; and the impacts of potential stockholder activism.

The company's forward-looking statements in this press release are based on management's current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this press release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

Non-GAAP Financial Information

This press release contains non-GAAP financial information related to organic sales growth / (decrease), adjusted EPS, and segment adjusted EBIT for the fourth quarter of fiscal year 2026 and for fiscal year 2026; as well as organic sales growth / (decrease) and adjusted EPS outlook for fiscal year 2027. The reasons management believes these measures are useful to investors are described below. Certain non-GAAP financial measures may be considered in determining incentive compensation. Clorox defines organic sales growth / (decrease) as GAAP net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions or divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the company was operating and expects to continue to operate throughout the relevant periods, and the company's estimate of the impact of foreign exchange rate changes, which are difficult to predict and out of the control of the company and management. However, organic sales growth / (decrease) may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments. Organic Sales, Adjusted Cost of Products Sold, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Selling and Administrative expenses, Adjusted Other Income (Expense), Adjusted Net Earnings Attributable to Clorox, and Adjusted Diluted Net Earnings Per Share are calculated in accordance with GAAP, that excludes or has otherwise been adjusted for significant items that are nonrecurring or unusual that are not indicative of the Company's underlying operations. The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. Non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments. Adjusted EBIT represents earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual that are not indicative of the Company's underlying operations. The company uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance, and allocate resources to each segment. Adjusted EBIT may not be the same as similar measures provided by other companies due to potential differences in methods of calculation or differences in which items are incorporated into these adjustments. The Non-GAAP measures listed above are supplemental information that management uses to help evaluate the company's historical and prospective financial performance on a consistent basis over time. Management believes that by adjusting for certain items affecting comparability of performance over time, such as the pension settlement charge, incremental costs and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the digital capabilities and productivity enhancements investment, transaction and integration costs related to acquisitions, significant losses related to divestitures and other nonrecurring or unusual items, investors and management are able to gain additional insight into the company's underlying operating performance on a consistent basis over time. The reconciliation tables below refer to the equivalent GAAP measures adjusted as applicable for the following items: Acquisition and Integration Costs 

On April 1, 2026, the Company completed the previously announced acquisition of GOJO Industries. As a result of this transaction, various acquisition and integration-related costs were and will be incurred related to the acquisition and efforts to integrate the recently acquired business to the Company's systems and processes. These costs include inventory step-up charges representing expense recognition of fair value adjustments in excess of the historical cost basis of inventory obtained through the acquisition, as well as direct acquisition transaction costs and legal-entity, operational, manufacturing, and information technology integration costs.

Due to the nature, scope and magnitude of these costs and recoveries, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

Digital Capabilities and Productivity Enhancements Investment

As announced in August 2021, the company invested in transformative technologies and processes over a five-year period beginning in fiscal year 2022 and completed during the third quarter of fiscal year 2026. The investment included replacement of the company's ERP system and transitioning to a cloud-based platform as well as the implementation of a suite of other digital technologies. The total incremental transformational investment was approximately $580 million. It is expected that these implementations will generate efficiencies and transform the company's operations in the areas of supply chain, digital commerce, innovation, brand building and more over the long term.

Of the total investment, approximately 75% represented incremental operating costs primarily recorded within selling and administrative expenses to be adjusted from reported EPS for purposes of disclosing adjusted EPS. About 70% of these operating costs were related to the implementation of the ERP, with the remaining costs primarily related to the implementation of complementary technologies.

Due to the nature, scope and magnitude of this investment, these costs were considered by management to represent incremental transformational costs above the historical normal level of spending for information technology to support operations. Since these strategic investments, including incremental operating costs, ceased at the end of the investment period, are not expected to recur in the foreseeable future and are not considered representative of the company's underlying operating performance, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period-over-period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

The following tables provide reconciliations of organic sales growth/(decrease) (non-GAAP) to net sales growth/(decrease), the most comparable GAAP measure:

Three months ended June 30, 2026

Percentage change versus the year-ago period

Health and
Wellness

Household

Lifestyle

International

Total
Company (1)

Net sales growth / (decrease) (GAAP)

16 %

(18) %

(17) %

4 %

(2) %

Add: Foreign Exchange







(3)

(1)

Add/(Subtract): Divestitures/Acquisitions (2)

(28)







(10)

Organic sales growth / (decrease) (non-GAAP)

(12) %

(18) %

(17) %

1 %

(13) %

Twelve months ended June 30, 2026

Percentage change versus the year-ago period

Health and
Wellness

Household

Lifestyle

International

Total
Company (1)

Net sales growth / (decrease) (GAAP)

— %

(11) %

(14) %

5 %

(5) %

Add: Foreign Exchange







(3)



Add/(Subtract): Divestitures/Acquisitions (2)

(8)







(3)

Organic sales growth / (decrease) (non-GAAP)

(8) %

(11) %

(14) %

2 %

(8) %

(1) 

Total Company includes Corporate and Other. Corporate and Other includes the results of the Better Health VMS business through the date of divestiture. 

(2) 

The divestiture impact is calculated as net sales from the Better Health VMS business after the sale date in the twelve month year-ago period. The acquisition impact is calculated as net sales from GOJO after the acquisition date in the current three and twelve month periods.

The following tables provide reconciliations of adjusted non-GAAP line items to the most comparable GAAP measure:

Reconciliation of Non-GAAP Measures

Three months ended June 30, 2026

As Reported
GAAP

Acquisition and
integration costs

Adjusted

(non-GAAP)

Cost of products sold

$            1,144

$                (30)

$            1,114

Gross profit

804

30

834

Gross margin

41.3 %

42.8 %

Selling and administrative expenses

298

(21)

277

Percent of net sales

15.3 %

14.2 %

Other (income) expense, net

(10)



(10)

Net earnings attributable to Clorox

163

39

202

Diluted net earnings per share

$              1.34

$              0.32

$              1.66

Reconciliation of Non-GAAP Measures

Twelve months ended June 30, 2026

As Reported
GAAP

Acquisition and
integration costs

Digital capabilities
and productivity
enhancements
investment

Adjusted

(non-GAAP)

Cost of products sold

$            3,876

$                (31)

$                 —

$            3,845

Gross profit

2,844

31



2,875

Gross margin

42.3 %

42.8 %

Selling and administrative expenses

1,066

(27)

(59)

980

Percent of net sales

15.9 %

14.6 %

Other (income) expense, net

(8)





(8)

Net earnings attributable to Clorox

587

44

45

676

Diluted net earnings per share

$              4.81

$              0.36

$              0.36

$              5.53

The following tables provide reconciliations of adjusted diluted earnings per share (non-GAAP) to diluted earnings per share, the most comparable GAAP measure:

Adjusted Diluted Earnings Per Share (EPS)

(Dollars in millions except per share data)

Diluted earnings per share

Three months ended

6/30/2026

6/30/2025

% Change

As reported (GAAP)

$         1.34

$         2.68

(50) %

Acquisition and integration costs (2)

0.32



Digital capabilities and productivity enhancements investment (4)



0.19

As adjusted (Non-GAAP)

$         1.66

$         2.87

(42) %

Diluted earnings per share

Twelve months ended

6/30/2026

6/30/2025

% Change

As reported (GAAP)

$         4.81

$         6.52

(26) %

Loss on divestiture (1)



0.94

Acquisition and integration costs (2)

0.36



Cyberattack costs, net of insurance recoveries (3)



(0.42)

Digital capabilities and productivity enhancements investment (4)

0.36

0.68

As adjusted (Non-GAAP)

$         5.53

$         7.72

(28) %

(1)

During the twelve months ended June 30, 2025, the company incurred an after tax charge of $118 related to the divestiture of the Better Health VMS business.

(2)

During the three and twelve months ended June 30, 2026, the company incurred approximately $51 ($39 after tax) and $58 ($44 after tax), respectively of costs related to the GOJO acquisition.

(3)

During the twelve months ended June 30, 2025, the company recognized approximately $70 ($53 after tax) of insurance recoveries related to the cyberattack.

(4)

During the three and twelve months ended June 30, 2026, the company incurred $0 and approximately $59 ($45 after tax), respectively, and during the three and twelve months ended June 30, 2025, the company incurred approximately $30 ($23 after tax) and $111 ($85 after tax), respectively, of operating expenses related to its digital capabilities and productivity enhancements investment. The expenses relate to the following:

Three months ended

Twelve months ended

6/30/2026

6/30/2025

6/30/2026

6/30/2025

External consulting fees (a)

$           —

$           22

$           46

$           78

IT project personnel costs (b)



2

3

7

Other (c)



6

10

26

Total

$           —

$           30

$           59

$          111

(a) 

Comprised of third-party consulting fees incurred to assist in the project management and end-to-end systems integration of this transformative investment. The company relies on consultants for certain capabilities required for these programs that the company does not maintain internally. These costs support the implementation of these programs incremental to the company's normal IT costs and will not be incurred following implementation.

(b) 

Comprised of labor costs associated with internal IT project management teams that are utilized to oversee the new system implementations. Given the magnitude and transformative nature of the implementations planned, the necessary project management costs are incremental to the historical levels of spend and will no longer be incurred subsequent to implementation. As a result of this long-term strategic investment, the company considers these costs not reflective of the ongoing costs to operate its business.

(c) 

Comprised of various other expenses associated with the company's new system implementations, including company personnel dedicated to the project that have been backfilled with either permanent or temporary resources in positions that are considered part of normal operating expenses.

The following tables provide reconciliations of adjusted EBIT (non-GAAP) to earnings (losses) before income taxes, the most comparable GAAP measure:

Reconciliation of earnings (losses) before income taxes to adjusted EBIT

Three months ended

Twelve months ended

6/30/2026

6/30/2025

6/30/2026

6/30/2025

Earnings (losses) before income taxes

$        213

$        410

$        791

$      1,078

Interest income

(1)

(2)

(8)

(9)

Interest expense

55

22

130

88

Loss on divestiture







118

Acquisition and integration costs

51



58



Cyberattack costs, net of insurance recoveries







(70)

Digital capabilities and productivity enhancements investment



30

59

111

Adjusted EBIT

$        318

$        460

$      1,030

$      1,316

Full year 2027 outlook
(estimated range)

Diluted earnings per share

Low

High

As estimated (GAAP)

$         5.41

$         5.71

Acquisition and integration costs (1)

0.29

0.29

As adjusted (Non-GAAP)

$         5.70

$         6.00

(1)  In fiscal year 2027, the company expects to incur approximately $46 ($35 after tax) of costs related to the GOJO acquisition.

Condensed Consolidated Statements of Earnings

Dollars in millions, except per share data

Three months ended

Twelve months ended

6/30/2026

6/30/2025

6/30/2026

06/30/2025

(Unaudited)

(Unaudited)

(Unaudited)

Net sales

$        1,948

$        1,988

$        6,720

$        7,104

Cost of products sold

1,144

1,064

3,876

3,891

Gross profit

804

924

2,844

3,213

Selling and administrative expenses

298

296

1,066

1,124

Advertising costs

216

171

749

770

Research and development costs

32

32

116

121

Loss on divestiture







118

Interest expense

55

22

130

88

Other (income) expense, net

(10)

(7)

(8)

(86)

Earnings before income taxes

213

410

791

1,078

Income taxes

46

74

190

254

Net earnings

167

336

601

824

Less: Net earnings attributable to noncontrolling interests

4

4

14

14

Net earnings attributable to Clorox

$          163

$          332

$          587

$          810

Net earnings per share attributable to Clorox

Basic net earnings per share

$          1.34

$          2.70

$          4.82

$          6.56

Diluted net earnings per share

$          1.34

$          2.68

$          4.81

$          6.52

Weighted average shares outstanding (in thousands)

Basic

121,504

123,173

121,775

123,525

Diluted

121,809

123,744

122,132

124,287

Reportable Segment Information

(Unaudited)

Dollars in millions

Net sales

Net sales

Three months ended

Twelve months ended

6/30/2026

6/30/2025

% Change(1)

6/30/2026

6/30/2025

% Change(1)

Health and Wellness 

$       860

$       741

16 %

$     2,697

$     2,697

— %

Household

524

639

(18) %

1,787

2,001

(11) %

Lifestyle

280

339

(17) %

1,123

1,303

(14) %

International

281

269

4 %

1,113

1,065

5 %

Reportable segment total

$     1,945

$     1,988

$     6,720

$     7,066

Corporate and Other (2)

3



100 %



38

(100) %

Total

$     1,948

$     1,988

(2) %

$     6,720

$     7,104

(5) %

Segment adjusted EBIT

Segment adjusted EBIT

Three months ended

Twelve months ended

6/30/2026

6/30/2025

% Change(1)

6/30/2026

6/30/2025

% Change(1)

Health and Wellness 

$       206

$       243

(15) %

$       678

$       840

(19) %

Household

69

156

(56) %

192

325

(41) %

Lifestyle

38

94

(60) %

208

290

(28) %

International

27

23

17 %

113

110

3 %

Reportable segment total

$       340

$       516

$     1,191

$     1,565

Corporate and Other (2)

(22)

(56)

(161)

(249)

Interest income

1

2

8

9

Interest expense

(55)

(22)

(130)

(88)

Loss on divestiture (3)







(118)

Acquisition and integration costs (4)

(51)



(58)



Cyberattack costs, net of insurance recoveries (5)







70

Digital capabilities and productivity enhancements investment (6)



(30)

(59)

(111)

Earnings (losses) before income taxes

$       213

$       410

(48) %

$       791

$     1,078

(27) %

(1) 

Percentages based on rounded numbers.

(2) 

Corporate and Other includes the Better Health VMS business.

(3) 

Represents the loss on divestiture of the Better Health VMS business of $118 after tax for the twelve months ended June 30, 2025.

(4) 

Represents expenses related to the company's acquisition and integration of GOJO of $51 ($39 after tax) and $58 ($44 after tax) for the three and twelve months ended June 30, 2026, respectively.

(5) 

Represents insurance recoveries related to the cyberattack of approximately $70 ($53 after tax) for the twelve months ended June 30, 2025.

(6) 

Represents expenses related to the company's digital capabilities and productivity enhancements investment of $0 and $59 ($45 after tax) for the three and twelve months ended June 30, 2026, respectively, and $30 ($23 after tax) and $111 ($85 after tax) for the three and twelve months ended June 30, 2025, respectively. 

Condensed Consolidated Balance Sheets

Dollars in millions

6/30/2026

6/30/2025

(Unaudited)

ASSETS

Current assets

Cash and cash equivalents

$

143

$

167

Receivables, net

791

821

Inventories, net

777

523

Prepaid expenses and other current assets

113

97

Total current assets

1,824

1,608

Property, plant and equipment, net

1,512

1,267

Operating lease right-of-use assets

401

333

Goodwill

1,945

1,229

Trademarks, net

989

502

Other intangible assets, net

606

64

Other assets

517

558

Total assets

$

7,794

$

5,561

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities

Notes and loans payable

$

1,086

$

4

Current maturities of long-term debt

1



Current operating lease liabilities

86

87

Accounts payable and accrued liabilities

1,600

1,828

Total current liabilities

2,773

1,919

Long-term debt

3,981

2,484

Long-term operating lease liabilities

366

305

Other liabilities

405

351

Deferred income taxes

17

20

Total liabilities

7,542

5,079

Commitments and contingencies

Stockholders' equity

Preferred stock





Common stock

131

131

Additional paid-in capital

1,312

1,319

Retained earnings

386

432

Treasury stock

(1,582)

(1,404)

Accumulated other comprehensive net (loss) income

(157)

(157)

Total Clorox stockholders' equity

90

321

Noncontrolling interests

162

161

Total stockholders' equity

252

482

Total liabilities and stockholders' equity

$

7,794

$

5,561

SOURCE The Clorox Company
2026-08-03 13:01 1mo ago
2026-08-03 07:30 1mo ago
Clorox zveřejní výsledky, čeká se pokles EPS i tržeb
CLX Clorox
FMP Stock News 78
Original source text
The Clorox Company (NYSE:CLX) will release its fourth quarter earnings report after the closing bell on Monday, Aug. 3.

Analysts expect the Oakland, California-based company to report quarterly earnings of $1.65 per share, down from $2.87 per share in the year-ago period. The consensus estimate for Clorox’s quarterly revenue is $1.91 billion. It reported $1.99 billion last year, according to Benzinga Pro.

On Friday, Clorox raised its quarterly dividend from $1.24 to $1.25 per share.

Shares of Clorox fell 1.2% to close at $95.53 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying CLX stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.
2026-07-31 21:29 1mo ago
2026-07-31 16:15 1mo ago
Clorox zvýšil čtvrtletní dividendu na 1,25 USD
CLX Clorox
FMP Stock News 92
Original source text
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The Clorox Company (NYSE: CLX) announced today that its board of directors has declared an increase to its quarterly dividend from $1.24 to $1.25 per share on the company's common stock. The dividend is payable August 28, 2026, to shareholders of record as of the close of business on August 12, 2026.

Clorox has a long history of providing value to its shareholders through regular dividend payments and annual dividend increases.

About The Clorox Company
The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Headquartered in Oakland, California since 1913, Clorox integrates sustainability into how it does business. Driven by consumer-centric innovation, the company is committed to delivering clearly superior experiences through its trusted brands including Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr®, Pine-Sol® and Purell® as well as international brands such as Chux®, Clorinda® and Poett®. Visit thecloroxcompany.com to learn more.   

CLX-C

SOURCE The Clorox Company

Also from this source
2026-07-30 16:38 1mo ago
2026-07-30 12:10 1mo ago
Clorox čeká pokles tržeb i zisku na akcii
CLX Clorox
FMP Stock News 78
Original source text
Key Takeaways Clorox's fiscal Q4 revenues are estimated to fall 4.1%, while earnings may decline 42.9%.ERP disruptions, weak category demand and slow Litter recovery are weighing on Clorox's performance.Clorox expects $20-$25 million in Q4 input-cost headwinds and 130 bps of margin pressure. The Clorox Company (CLX - Free Report) is scheduled to report fourth-quarter fiscal 2026 results on Aug. 3, after market close, and is likely to have registered declines in the top and bottom lines.

The Zacks Consensus Estimate for revenues is pegged at $1.91 billion, indicating a drop of 4.1% from the prior-year quarter’s reported figure. The consensus mark for quarterly earnings has moved down 5.2% in the past 30 days to $1.64 per share. The consensus mark indicates a decline of 42.9% from the prior-year quarter.

The Zacks Consensus Estimate for Clorox’s quarterly revenues is pegged at $6.7 billion, implying a 5.9% decline from the year-ago quarter’s reported number. For fiscal 2026, the consensus mark is pegged at $5.52 per share, suggesting 28.5% growth from the prior-year reported figure. The consensus mark has moved down 2.1% in the past 30 days.

The consumer and professional product company has a trailing four-quarter earnings surprise of 11.3%, on average. CLX surpassed earnings estimates by 10.8% in the last reported quarter.

Factors Likely to Influence CLX’s Q4 ResultsClorox entered fiscal 2026 with expectations that the back half of the year would mark a return to stronger execution after ERP-related disruptions. However, on the last reported quarter’s earnings call, management acknowledged that the anticipated recovery has been slower than expected, with the fiscal third-quarter results falling short of internal expectations. While the company cited continued strength in cleaning products and international markets, several businesses failed to recover at the expected pace, resulting in weaker-than-planned market share gains and margin performance.

Several of Clorox's important categories continue to experience operational and competitive headwinds despite heavy investments. Fresh Step litter, one of the company's largest turnaround priorities, is undergoing a complete product reset involving new formulations, packaging, pricing architecture and SKU conversions. Meanwhile, the Food segment faces declining category demand, aggressive competitive discounting and potential consumer shifts related to GLP-1 weight-loss drug adoption. Although Hidden Valley has launched products and adjusted packaging, management admitted category weakness remains a drag.

On the last reported quarter’s earnings call, management admitted that the turnaround in its Litter business will be a "multi-year process," suggesting that a meaningful recovery remains some distance away. The company also admitted that Food categories have been underperforming due to weaker category demand and heightened promotional intensity. Although management remains optimistic about fiscal 2027, the latest commentary suggests that restoring consistent organic sales momentum will require more time than previously anticipated.

Clorox has been confronting multiple layers of cost pressure that threaten profitability in the fiscal fourth quarter and beyond. Management highlighted higher-than-expected supply-chain expenses, delayed productivity savings due to ERP stabilization and a sharp increase in commodity costs following higher oil prices.

For fourth-quarter fiscal 2026 alone, the company expects $20-$25 million in incremental input-cost headwinds, equivalent to roughly 130 basis points (bps) in gross margin pressure, without any meaningful mitigation actions yet in place. While management emphasized confidence in their pricing and productivity toolkit, it also admitted that fiscal 2027 remains highly uncertain, given volatile energy markets and geopolitical developments.

Apart from inflationary pressures, the GOJO acquisition introduces temporary gross-margin dilution and one-time integration costs, further weighing on profitability. The combination of elevated commodity inflation, deferred cost savings and acquisition-related expenses creates a difficult earnings backdrop, leaving investors exposed to additional estimate revisions if cost inflation persists longer than management currently anticipates.

Clorox expects fiscal 2026 net sales to decline 6%, including a slightly less than 3-percentage-point benefit from the GOJO Industries acquisition, less than one point of headwind from the VMS divestiture and a modest foreign exchange tailwind. Organic sales are projected to decline 9%, reflecting a 7.5-point drag from the reversal of incremental shipments made ahead of last year’s ERP transition.

For fiscal 2026, management expects the gross margin to fall 250-300 bps, including about 60 bps of headwinds from the GOJO acquisition, 100 bps tied to the ERP shipment reversal and additional headwinds from higher energy costs tied to the Middle East conflict. This setup raises the bar for execution in productivity and revenue management.

Our model predicts gross profit to decline 14.7% year over year to $788.2 million in fourth-quarter fiscal 2026. The gross margin is expected to have contracted 540 bps to 41.1% in the quarter under review. Our model expects operating income to decline 37.9% year over year in the fiscal fourth quarter, with an 820-bps contraction in operating margin.

What the Zacks Model Unveils for CLXOur proven model does not conclusively predict an earnings beat for Clorox this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.

Clorox has an Earnings ESP of -3.52% and a Zacks Rank #4 (Sell) at present.

CLX’s Valuation & Price PerformanceFrom the valuation standpoint, Clorox has a forward 12-month price-to-earnings ratio of 16.43X, which is below the industry’s average of 18.93X. Also, the stock is trading below its five-year high of 35.61X.

Image Source: Zacks Investment Research

CLX shares have risen 14.4% in the past three months compared with the industry’s growth of 5.3%.

Image Source: Zacks Investment Research

Stocks With the Favorable CombinationHere are companies that, according to the model, have the right combination of elements to beat on earnings this reporting cycle.

Archer Daniels Midland Company (ADM - Free Report) currently has an Earnings ESP of +3.43% and a Zacks Rank #2. ADM is anticipated to register top- and bottom-line growth when it reports second-quarter 2026 results. The Zacks Consensus Estimate for Archer Daniels’ quarterly revenues is pegged at $22.4 billion, indicating growth of 5.7% from the year-ago quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.

The consensus estimate for Archer Daniels’ earnings is pegged at $1.27 per share, which indicates growth of 36.6% from the year-ago quarter. ADM delivered an earnings surprise of 5.4% in the trailing four quarters, on average.

Newell Brands Inc. (NWL - Free Report) has an Earnings ESP of +5.36% and a Zacks Rank #2 at present. NWL is likely to register top-line growth when it releases second-quarter 2026 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $1.97 billion, implying growth of 1.7% from the year-ago quarter.

The consensus estimate for Newell Brands’ quarterly earnings currently stands at 19 cents per share, suggesting a decline of 20.8% from the year-ago quarter. NWL has a trailing four-quarter average earnings surprise of 9.7%.

Church & Dwight Co. (CHD - Free Report) has an Earnings ESP of +3.53% and a Zacks Rank of 3 at present. CHD is likely to register top- and bottom-line declines when it releases second-quarter 2026 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $1.5 billion, implying a decline of 0.2% from the year-ago quarter’s actual.

The consensus estimate for Church & Dwight’s quarterly earnings of 89 cents per share indicates a decline of 5.3% from the year-ago quarter’s reported number. CHD has a trailing four-quarter average earnings surprise of 6.5%.
2026-07-14 16:19 1mo ago
2026-07-14 10:35 1mo ago
Clorox roste v segmentu Household, brzdí ho Litter a Food
CLX Clorox
FMP Stock News 72
Original source text
Key Takeaways Clorox's Cleaning business is gaining share as PURE and Scentiva launches beat expectations.Litter packaging, pricing and shelf-placement changes are slowing recovery despite distribution gains.ERP completion, shelf resets and pricing actions are expected to improve execution across the portfolio. The Clorox Company's (CLX - Free Report) Household segment remains its biggest source of stability, but recent commentary suggests that strength in one business alone may not be enough to drive broader growth. While the segment continues to benefit from solid demand in cleaning products and successful innovation, weakness in a few other categories is weighing on the company's overall momentum.

Management highlighted that the Cleaning business is the portfolio's standout performer. Product launches, including the Clorox PURE allergen platform and additions to the Scentiva lineup, are gaining shelf space, generating strong early consumer response and outperforming internal expectations. Despite an intensely promotional environment, the company has said that it continues to gain market share in cleaning, reinforcing the strength of its flagship brands.

However, the positive momentum in Household is being offset elsewhere. Fresh Step cat litter remains in the middle of a multi-year transformation, with new packaging, product claims and pricing architecture creating temporary disruption. Although distribution gains have met expectations, shelf placement issues and the complexity of converting shoppers to new products have slowed the recovery. Management also acknowledged that Food categories remain under pressure from elevated promotions and weaker-than-expected category demand.

Clorox believes execution rather than demand is the key variable. With the ERP rollout completed, management expects better service levels, stronger on-shelf execution and faster commercialization of innovation. Retail distribution points increased more than 5% in the third quarter of fiscal 2026, while additional shelf resets are expected through the fourth quarter. The company is also expanding revenue growth management initiatives, targeted pricing actions and brand investments to strengthen value perception.

The Household segment provides an important foundation, but Clorox's ability to sustain long-term growth will ultimately depend on whether improvements in Litter, Food and other businesses can match the momentum already visible in Cleaning.

CLX’s Price Performance, Valuation & EstimatesShares of the Zacks Rank #4 (Sell) company have lost 7.6% in the past three months against the industry’s growth of 5%.

Image Source: Zacks Investment Research

From a valuation standpoint, CLX trades at a forward price-to-earnings ratio of 15.66X compared with the industry’s average of 17.59X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CLX’s fiscal 2026 earnings implies a year-over-year decline of 27.3%, while that of fiscal 2027 shows growth of 11.5%. The company’s EPS estimate for fiscal 2026 has been unchanged in the past 30 days.

Image Source: Zacks Investment Research

Stocks to Consider in the Consumer Staples SpaceUnited Natural Foods (UNFI - Free Report) is the leading distributor of natural, organic and specialty food and non-food products in the United States and Canada. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for United Natural Foods’ current financial-year EPS indicates growth of a whopping 254.9% from the prior-year reported level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.

Church & Dwight Co. Inc. (CHD - Free Report) develops, manufactures and markets a broad range of household, personal care and specialty products. The company currently has a Zacks Rank of 2 (Buy).

The Zacks Consensus Estimate for CHD’s 2026 EPS indicates growth of 6.2% from the previous year’s reported figure. Church & Dwight delivered a trailing four-quarter average earnings surprise of 6.5%.

Krispy Kreme (DNUT - Free Report) operates as a branded retailer and wholesaler of doughnuts, coffee and other complementary beverages and treats and packaged sweets. The company currently carries a Zacks Rank of 2.

The Zacks Consensus Estimate for Krispy Kreme’s current financial-year EPS indicates growth of 30% from the year-ago reported number. DNUT delivered a trailing four-quarter negative earnings surprise of 6.3%, on average.
2026-07-13 21:08 1mo ago
2026-07-13 16:30 1mo ago
Clorox oznámí výsledky za 4. čtvrtletí a fiskální rok 2026 3. srpna 2026
CLX Clorox
FMP Stock News 78
Original source text
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The Clorox Company (NYSE: CLX) will issue its fourth-quarter and fiscal year 2026 results on August 3, 2026. Timing for the announcement will be as follows:

1:15 p.m. PT / 4:15 p.m. ET: Press release and prepared management remarks posted on the company's website 2 p.m. PT / 5 p.m. ET: Live Q&A audio webcast for analysts with Chair and CEO Linda Rendle and Chief Financial Officer Luc Bellet Links to the webcast, press release and prepared remarks can be found at Clorox quarterly results.

About The Clorox Company
The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Headquartered in Oakland, California since 1913, Clorox integrates sustainability into how it does business. Driven by consumer-centric innovation, the company is committed to delivering clearly superior experiences through its trusted brands including Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr®, Pine-Sol® and Purell® as well as international brands such as Chux®, Clorinda® and Poett®. Visit thecloroxcompany.com to learn more.   

CLX-F

SOURCE The Clorox Company

Also from this source